Translating a Mayo Clinic stem-cell discovery, a global team has demonstrated that therapy with cardiopoietic (cardiogenically-instructed) or “smart” stem cells can improve heart health for people suffering from heart failure. Here is the first application in patients of lineage-guided stem cells for targeted regeneration of a failing organ, paving how you can progression of next generation regenerative medicine solutions. This study was published online on the Journal with the American College of Cardiology.
The multi-center, randomized Cardiopoietic stem cell therapy in heart failure (C-CURE) trial involved heart failure patients from Belgium, Switzerland and Serbia. Patients from the control group received standard maintain heart failure as per established guidelines. Patients within the cell therapy arm received, as well as standard care, cardiopoietic stem cells — economic crisis-in-class biotherapeutic. In this process, marrow was harvested in the the surface of the patient’s hip, and isolated stem cells were treated with a protein cocktail to copy natural cues of heart development. Derived cardiopoietic stem cells were then injected into your patient’s heart.
“Cells underwent a cutting-edge treatment to optimize their repair capacity,” says Andre Terzic, M.D., Ph.D., study senior author and director from the Mayo Clinic Center for Regenerative Medicine. “This research helps us move beyond the science fiction notion of stem cell research, providing clinical evidence to get a new approach in cardiovascular regenerative medicine.”
Every patient in the stem cell treatment group improved. Heart pumping function improved in each patient within 6 months following cardiopoietic stem cell treatment. Furthermore, patients experienced improved fitness and could walk longer distances than before stem cell therapy. “The main benefit to patients who received cardiopoietic stem cell therapy was significant,” Dr. Terzic says.
Within the accompanying editorial, Charles Murry, M.D., Ph.D., and colleagues at the University of Washington, Seattle, say, “Few months after treatment, the cell therapy group a 7 percent absolute improvement in EF (ejection fraction) over baseline, versus a non-significant alternation in the control group. This improvement in EF is dramatic, particularly given the duration between your ischemic injury and cell therapy. It compares favorably with the most powerful therapies in coronary failure.”
The science supporting this trial is a product of the decade-long journey in decoding principles of stem cell-based heart repair. “Discovery of rare stem cells that can inherently promote heart regeneration provided an important clue. In after that natural blueprint, we further developed the know-how necessary to convert patient-derived stem cells into cells which could reliably repair a failing heart,” says Dr. Terzic, underscoring the team effort on this endeavor.
Initial discovery ended in the identification of hundreds of proteins associated with cardiogenesis, or even the heart development process. The study team then identified which proteins are necessary in assisting a stem cell turn into reparative cell type, ultimately causing development of a protein cocktail-based procedure that orients stem cells for heart repair. Such upgraded stem cells these are known as cardiopoietic or heart creative.
Mayo Clinic partnered with Cardio3 Biosciences, a bioscience company in Mont-Saint-Guibert, Belgium, for advanced product development, manufacturing scale-up, and clinical test execution.
Reference: Jozef Bartunek, MD, PhD, Atta Behfar, MD, PhD, Dariouch Dolatabadi, MD, Marc Vanderheyden, MD, Miodrag Ostojic, MD, PhD, Jo Dens, MD, PhD, Badih El Nakadi, MD, Marko Banovic, MD, Branko Beleslin, MD, PhD, Mathias Vrolix, MD, PhD, Victor Legrand, MD, PhD, Christian Vrints, MD, PhD, Jean Louis Vanoverschelde, MD, PhD, Ruben Crespo-Diaz, PhD, Christian Homsy, MD, Michal Tendera, MD, PhD, Scott Waldman, MD, PhD, William Wijns, MD, PhD, Andre Terzic, MD, PhD, Cardiopoietic stem cell therapy in heart failure. The C-CURE multicenter randomized trial with lineage-specified biologics, Journal of the American College of Cardiology, 2013.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.